ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress

Source: iStockAnalyst

MOUNTAIN VIEW, Calif., May 26, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), today announced the presentation of results from the Company's development program for CCX168, an investigational orally administered inhibitor ...
Full article at: iStockAnalyst  More like this  24 minutes ago

Advertisement

ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal

Source: Bloomberg.com

ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress MOUNTAIN VIEW, Calif., May 26, 2012 (GLO ...
Full article at: Bloomberg.com  More like this  1 hour ago

Biogen Tysabri Canadian Label Update - Analyst Blog

Source: Zacks Investment Research

Biogen Idec (BIIB - Analyst Report) recently announced that Health Canada has approved a change in the label of its multiple sclerosis (MS) drug, Tysabri. The new label of the drug indicates anti-JC virus (JCV) antibody status a ...
Full article at: Zacks Investment Research  More like this  11 hours ago, 4:17pm CDT

Latest stories

Chevrolet Recalls 2013 Malibu Eco for Airbag Deployment Issue
Airbags could go off unexpectedly in some models

 

Fox, CBS, and NBC Sue Dish Network for Cutting Commercials
AutoHop under fire

 

Class-action Suit Filed Against Facebook over IPO Issues
Facebook hit with suit

 

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2

Source: Seeking Alpha

This is a continuation of my previous article on biotechnology stocks to watch ahead of ASCO 2012. In this article, I cover the second set of stocks that are presenting at ASCO 2012. Biotech stocks are high risk/reward stocks, and there ...
Full article at: Seeking Alpha  More like this  18 hours ago, 9:17am CDT

New Mesothelioma Clinical Trial Discussed in Open-to-Public Teleconference

Source: Emediawire.com

A recording of the call can be obtained by visiting the Meso Foundation’s website at curemeso.org/meettheexperts. Last night, as part of the “Meet the Experts” podcasts presented exclusively by the Meso Foundation, Dr. Raffit Hassan, Senior Investigat ...
Full article at: Emediawire.com  More like this  20 hours ago, 8:05am CDT

Progenics Pharma: Several Short Term Catalysts With Good Long Term Fundamentals

Source: Seeking Alpha

In a recent catalyst stock pick article, I wrote about a company named Progenics Pharma (PGNX) which trades for around $8.10 a share with a $274.61M market cap. This company is located in Tarrytown, NY and develo ...
Full article at: Seeking Alpha  More like this  20 hours ago, 7:57am CDT

You’re slowly being poisoned

Source: HealthierTalk.com

Want a shock? Go get tested for heavy metals. Your jaw will drop when you see the results. I know, because I see the reactions in my own clinic every single day. The reality is, nearly everyone has way too much lead, mercu ...
Full article at: HealthierTalk.com  More like this  20 hours ago, 7:56am CDT

New Drugs For Bad Bugs? John Rex Discusses

Source: Pharmalot

Yesterday, several European drugmakers – including GlaxoSmithKline and Sanofi – agreed to work with leading academics to combat antimicrobial resistance and speed the delivery of new antibiotics. The $285 million effort, called NewDr ...
Full article at: Pharmalot  More like this  20 hours ago, 7:55am CDT

European Medicines Agency Confirms Positive Benefit-Risk Balance of Mabthera

Source: Drugs.com

Batches produced at the Vacaville manufacturing site do not pose risk to public health Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines Agency’s Committee for Medicinal Products for Human ...
Full article at: Drugs.com  More like this  20 hours ago, 7:24am CDT